Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management

Stepczynska, A., Schanstra, J. P. and Mischak, H. (2016) Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis, 8(5), pp. 439-455. (doi: 10.4155/bio.16.8) (PMID:26891752)

[img]
Preview
Text
117862.pdf - Accepted Version

1MB

Abstract

The recent advancements in clinical proteomics enabled identification of biomarker panels for a large range of diseases. A number of CE-MS-identified biomarker panels were verified and implemented in clinical studies. Despite multiple challenges, accumulating evidence supports the value and the need for proteome-based biomarker panels. In this perspective, we provide an overview of clinical studies indicating the added value of CE-MS biomarker panels over traditional diagnostics and monitoring methods. We outline apparent advantages of applying novel proteomic biomarker panels for disease diagnosis, prognosis, staging, drug development and patient management. Facing the plethora of benefits associated with the use of CE-MS biomarker panels, we envision their implementation into the medical practice in the near future

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mischak, Professor Harald
Authors: Stepczynska, A., Schanstra, J. P., and Mischak, H.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Bioanalysis
Publisher:Future Science Ltd.
ISSN:1757-6180
ISSN (Online):1757-6199
Copyright Holders:Copyright © 2016 Future Science Ltd.
First Published:First published in Bioanalysis 8(5):439-455
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record